Discovery STREAM

  1. BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D. 2/26/2023

    Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here. 

  2. Is Evaporation Important For Optical Biosensors? 2/17/2022

    If your sample is open to evaporation effects causing your concentration to change, will your data, and potentially your conclusions, be unreliable?

  3. Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 10/20/2025

    In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

  4. LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma 2/17/2025

    This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

  5. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

    Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

  6. Can Kinetics Provide Detailed Information About Binding Interactions? 2/17/2022

    See the potential value kinetics brings to deepen the understanding of biological processes.

  7. Don't Be A D**k With Ochre Bio's Dr. Quin Wills 9/27/2023

    Don't be offended by the title of today's Business of Biotech podcast. Dr. Quin Wills' application of what's become known as "Wheaton's Law" (look it up) is central to the ambitious goals his company, Ochre Bio, is pursuing: pioneering the value of computational biology in large mol discovery and development, putting an end to the global liver disease epidemic, and changing the costly, high-risk approach to clinical trials. On this week's episode, Dr. Wills and I explore how those goals are being addressed despite the challenges they present, and how the company's three guiding principles, don't be a d**k being one of them, align the Ochre team with the mission at hand. 

  8. Meet Your Bioprocess Sidekick For Cell Culture Media Analysis 6/10/2022

    You need rapid and reliable nutrient profiles to make informed decisions, and waiting on that data has detrimental effects on your process. See how REBEL fills the gap.

  9. Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup 2/17/2025

    By leveraging this innovative combination, the assay achieves detection limits comparable to traditional methodologies while enhancing overall efficiency and reliability.

  10. Elucidating The Role Of IL-18 In NSCLC Integrated Analysis 1/23/2025

    Hear how imaging mass cytometry, CyTOF, and single-cell sequencing unlock the secrets of the tumor microenvironment. Discover new insights into IL-18 and its impact on non-small cell lung cancer.